LVPEI raises awareness and funds for retinoblastoma treatment with WHITATHON Run
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Lupin updates on shipment of Mirabegron ER Tablets
The product is used to treat amyotrophic lateral sclerosis
Subscribe To Our Newsletter & Stay Updated